Singapore markets closed

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
46.69-0.16 (-0.34%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close46.85
Bid0.00 x 0
Ask0.00 x 0
Day's range46.65 - 47.04
52-week range43.85 - 66.00
Avg. volume79,695
Market cap35.084B
Beta (5Y monthly)0.57
PE ratio (TTM)27.46
EPS (TTM)1.70
Earnings dateN/A
Forward dividend & yield0.39 (0.84%)
Ex-dividend date09 May 2023
1y target estN/A
  • Business Wire

    Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies

    BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.

  • Reuters

    European stocks fall on earnings jitters, rate hike worries

    (Reuters) -European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.

  • Reuters

    Lonza to buy back $2.17 billion worth of shares, backs mid-term growth

    (Reuters) -Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The firm, which is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins, as well as cell and gene therapies, also reported an almost 20% jump in core 2022 EBITDA of 2.0 billion Swiss francs, slightly ahead of market expectations.